ライフサイエンスコーパス: stomach cancer

1 tly improved survival for breast, colon, and stomach cancer.

2 D and VGPCs might be therapeutic targets for stomach cancer.

3 health, and is associated with incidence of stomach cancer.

4 er), with a notably high frequency of 11% in stomach cancer.

5 n potentially be used for early diagnosis of stomach cancer.

6 ts for developing lncRNA-based therapies for stomach cancer.

7 lication for non-invasive early diagnosis of stomach cancer.

8 prevalent in survivorship of esophageal and stomach cancer.

9 and abolished G1 phase cell cycle arrest in stomach cancer.

10 genes that are significantly associated with stomach cancer.

11 that CD177 is a novel prognostic factor for stomach cancer.

12 as he read on the Internet that it can cause stomach cancer.

13 rectal cancer, and 16% (95% CI: 9%, 22%) for stomach cancer.

14 velopment of duodenal and gastric ulcers and stomach cancer.

15 genic infectious agent and the main cause of stomach cancer.

16 phoma, ovarian cancer, pancreatic cancer, or stomach cancer.

17 ustry and the risks of esophageal cancer and stomach cancer.

18 eloid leukemia, cleidocranial dysplasia, and stomach cancer.

19 ion of the gastric mucosa, which can lead to stomach cancer.

20 , lung cancer, nasopharyngeal carcinoma, and stomach cancer.

21 ral network-based model DOMSCNet to classify stomach cancer.

22 for lung cancer, and 4.6 to 53.6 (19.0%) for stomach cancer.

23 by DNA methylation in colorectal, breast and stomach cancer.

24 adder, esophagus, colon, lung, pancreas, and stomach cancers.

25 ents with MSI-H endometrial, colorectal, and stomach cancers.

26 n 73% of those with bladder, pancreatic, and stomach cancers.

27 er, ovarian, pancreatic, small cell lung, or stomach cancers.

28 instability-positive endometrial, colon, and stomach cancers.

29 obacter pylori is responsible for most human stomach cancers.

30 oesophageal reflux, gastritis, lymphoma, and stomach cancers.

31 -3.90), pancreatic cancer (2.35, 1.91-2.88), stomach cancer (1.96, 1.65-2.34), and lung cancer (1.68,

32 for rectal cancer, 25.7 to 55.5 (39.6%) for stomach cancer, 17.2 to 56.3 (34.1%) for pancreatic canc

33 ratios were 5.76 (95% CI, 2.12 to 15.6) for stomach cancer, 3.61 (95% CI, 1.33 to 9.79) for kidney c

34 ease (CVD), chronic kidney disease (CKD) and stomach cancer after implementation of (a) Australia's s

35 en (AAPC, -3.8%; 95% CI, -4.0% to -3.6%) and stomach cancer among women (AAPC, -3.4%; 95% CI, -3.6% t

36 BRCA2 mutation carriers are also at risk of stomach cancer and melanoma (of the skin and eye).

37 of cagA+ s1-type vacA H. pylori in cases of stomach cancer and ulcers as opposed to cases of gastrit

38 Risks of ovarian, breast, and stomach cancers and leukemias/lymphomas were increased n

39 s overexpressed in blood, breast, colon, and stomach cancers and promotes cell survival in the face o

40 ciations with violent and accidental deaths, stomach cancer, and alcohol- and smoking-related outcome

41 In case studies of breast cancer, stomach cancer, and colorectal cancer, 36/45 (80%) novel

42 y period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles.

43 nd other conditions, such as kidney disease, stomach cancer, and osteoporosis.

44 for ovarian cancer mortality (OR = 1.6), 2) stomach cancer as a risk factor for ovarian cancer morta

45 s in mortality from cerebrovascular disease, stomach cancer, colorectal cancer, lung cancer, breast c

46 ociated with a higher risk of colorectal and stomach cancers, coronary artery disease, and type 2 dia

47 developed a phylogenetic model for analyzing stomach cancer data.

48 The phylogenetic model was applied to the stomach cancer data.

49 , corresponding to about 1% of CVD, CKD, and stomach cancer deaths, and prevent some 1,920 (1,274 to

50 phageal cancer and 646 workers with incident stomach cancer diagnosed between 1989 and 1998 were comp

51 or early adulthood only were associated with stomach cancer, esophageal squamous cell carcinoma, and

52 istrict with the lowest probability; and for stomach cancer for men, being 3.2 times (2.6-4.1) higher

53 und a decreased risk of cancer, particularly stomach cancer, for participants taking a multivitamin s

54 In stomach cancers, high rates of Candida were linked to th

55 carcinoma (HR, 2.79; 95% CI, 1.27-6.12), and stomach cancer (HR, 4.11; 95% CI, 2.04-8.27).

56 -statistically significant increased risk of stomach cancer (HR: 1.54; 95% CI: 0.96,2.48), compared w

57 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and

58 take are known as important risk factors for stomach cancer in humans.

59 ross generations for liver cancer in men and stomach cancer in women.

60 s mutually and separately for colorectal and stomach cancers in relation to consumption of exclusivel

61 evalence of H. pylori, and, correspondingly, stomach cancer incidence and mortality, is significantly

62 In colon and stomach cancers, increased INHBA expression significantl

63 Treatment-related stomach cancer is an important cause of morbidity and mo

64 , the underlying mechanism of lncRNA GAS5 in stomach cancer is poorly understood.

65 Stomach cancer is the second most common cause of cancer

66 0.32; 95% CI, 0.27 to 0.39; P trend < .001), stomach cancer (men: HR, 0.87; 95% CI, 0.82 to 0.93; P t

67 eported to be a protective factor for either stomach cancer or esophageal cancer and therefore warran

68 k (OR 1.40; 95% CI 1.13-1.74; p = 0.002) and stomach cancer (OR 1.46; 95% CI 1.05-2.03; p = 0.024).

69 o (OR) = 1.9), colorectal cancer (OR = 1.6), stomach cancer (OR = 1.9), and lung cancer (OR = 1.7).

70 both esophageal cancer (p-trend = 0.01) and stomach cancer (p-trend < 0.001) when exposures were lag

71 Colorectal cancer, liver cancer, stomach cancer, pancreatic cancer, and esophageal cancer

72 our approach to 408 colon, liver, lung, and stomach cancer patients and controls, at 97.9% specifici

73 and tumor) were sequenced from each of five stomach cancer patients in different stages (I, II, III

74 ed risks persisted in subgroups such as male stomach cancer patients.

75 analysis of 25 case-control studies from the Stomach cancer Pooling Project to assess the association

76 This is a necessary step in order to move stomach cancer prevention forward to population-based pr

77 ent, community-based H. pylori screening and stomach cancer prevention is feasible and acceptable.

78 ake and plant-based foods seem promising for stomach cancer prevention, while vitamin C lowers the ri

79 For liver, oral, esophageal, and stomach cancer, rates decreased in younger adults in mor

80 Treatment with dacarbazine also increased stomach cancer risk (12 cases, nine controls; OR, 8.8; 9

81 (>/= 5,600 mg/m(2)) had strikingly elevated stomach cancer risk (25 cases, two controls; odds ratio

82 Stomach cancer risk increased with increasing radiation

83 d intake of fish was associated with a lower stomach cancer risk.

84 ry groups in risks of the following cancers: stomach cancer [RRs (95% CIs) compared with meat eaters:

85 g into the 5'-UTR of four proto-oncogenes in stomach cancer sequencing data.

86 For stomach cancer, the random-effects RR estimate was 0.53

87 In the meta-analyses of colorectal and stomach cancer, the reference categories ranged from no

88 The main risk factor for stomach cancer, the third most common cause of cancer de

89 und that lncRNA GAS5 had lower expression in stomach cancer tissues than the normal counterparts.

90 gh not statistically significant, the HR for stomach cancer was less than 1 among patients who took G

91 Stomach cancer was the country's leading cause of cancer

92 for soft tissue, head and neck, ovarian, and stomach cancers were also identified, and these have not

93 Kinase/Akt pathway alterations in breast and stomach cancer with mucinous differentiation.

94 ll differences by HDI category (eg, lung and stomach), cancers with intermediate median 3-year net su

95 therapy had dose-dependent increased risk of stomach cancer, with marked risks for patients who also

96 ies for specific delivery of therapeutics to stomach cancer without damaging normal cells and tissues

97 produce major regressions of pancreatic and stomach cancer xenografts.